Magainin-2 vs LL-37 — Peptide Comparison

Magainin-2 vs LL-37 — Peptide Comparison Magainin-2 vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Magainin-2 1–5 mg LL-37 0.5–1.6 mg/mL (topical) Frequency Multiple times daily Once daily Administration Topical application (primary clinical route) Topical application (wound healing) Cycle Length 4-6 weeks 12+ weeks Onset Speed Rapid (hours to days) Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Efficacy Fighting Infections Resistance Prevention Wound Healing Immune Boost Technical Data Molecular Formula C114H180N30O29S Molecular Weight 2,466.9 g/mol (magainin-2); Pexiganan (MSI-78): ~2,500 Da Half-Life Plasma half-life: minutes (rapid proteolytic degradation by serum proteases); local tissue persistence in wound environment: hours at therapeutic concentrations Bioavailability Topical bioavailability: local tissue concentrations achieve bactericidal levels with 1-2% cream formulation; systemic bioavailability minimal — rapidly degraded by tissue proteases if absorbed; poor oral bioavailability CAS Number 108433-95-0 C205H340N60O53 4,493.26 Da Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery 154947-66-7 Protocols standard 1% cream (pexiganan, a magainin-2 analog) Twice daily Up to 28 days Pexiganan (MSI-78), a synthetic magainin-2 analog, was tested as a 1% topical cream in Phase 3 diabetic foot-ulcer trials and matched oral ofloxacin for clinical improvement (~85-90%) [6]. Native magainin-2 itself has no approved human dosing; figures reflect its clinical-stage analog. starting 0.5 mg/mL gel Twice weekly 4 weeks Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4]. 1.6 mg/mL gel Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4]. Applications Research into topical antimicrobial peptides for diabetic foot ulcer management Magainin-2 is particularly well-suited for individuals focused on research into topical antimicrobial peptides for diabetic foot ulcer management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Understanding the toroidal pore model of antimicrobial peptide membrane disruption Magainin-2 is particularly well-suited for individuals focused on understanding the toroidal pore model of antimicrobial peptide membrane disruption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Development of resistance-proof antimicrobial agents targeting membrane architecture Magainin-2 is particularly well-suited for individuals focused on development of resistance-proof antimicrobial agents targeting membrane architecture. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Investigation of selective anticancer activity mediated by membrane phospholipid asymmetry Magainin-2 is particularly well-suited for individuals focused on investigation of selective anticancer activity mediated by membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Anti-biofilm strategies for chronic wound infections and medical device-associated infections LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Boosting innate immune defense in immunocompromised or aging individuals LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Application site burning/stinging Local erythema Mild pruritus Increased wound exudate Uncommon Contact sensitization Serious No serious systemic adverse effects documented Local site irritation Transient stinging or burning Mild perilesional erythema Allergic contact reaction Hemolytic activity at systemic concentrations Research Status FDA Status Research compound Safety Overview Magainin-2 demonstrates favorable safety in topical antimicrobial wound care studies with minimal systemic absorption through intact skin. Local tissue irritation minimal at therapeutic concentrations (0.1-1% w/w); hemolytic activity negligible at concentrations <10 μM. No serious adverse events in Phase II wound healing trials. Peptide stability dependent on formulation pH; activity preserved at physiologic pH. Resistance development slower than traditional antibiotics. Contraindications xKnown hypersensitivity to magainin peptides or amphibian-derived proteins xPregnancy and breastfeeding — insufficient safety data for magainin-derived therapeutics xDeep tissue infections requiring systemic antimicrobial therapy — topical magainin has limited tissue penetration depth xSevere peripheral vascular disease with non-viable tissue — antimicrobial peptides require viable tissue interface for effective action LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications. xKnown hypersensitivity to cathelicidin peptides or formulation components xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials xSevere renal impairment — peptide clearance may be altered Decision Guide Choose Magainin-2 if... Research into topical antimicrobial peptides for diabetic foot ulcer management Understanding the toroidal pore model of antimicrobial peptide membrane disruption Development of resistance-proof antimicrobial agents targeting membrane architecture Investigation of selective anticancer activity mediated by membrane phospholipid asymmetry Choose LL-37 if... Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) Anti-biofilm strategies for chronic wound infections and medical device-associated infections Boosting innate immune defense in immunocompromised or aging individuals